Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Safety and Tolerability Study of GB301 Given as a Single Intravenous Dose in Subjects With Mild to Moderate Alzheimer's Disease

Authors not listed

VTBIO Co. LTD · 2019

Abstract

The primary objective of this study is to evaluate the safety and tolerability of multiple intravenous (IV) infusions at a single dose strength of GB301 in subjects with mild to moderate AD.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-11 MST

Cite this

APA
Anonymous. (2019). A Safety and Tolerability Study of GB301 Given as a Single Intravenous Dose in Subjects With Mild to Moderate Alzheimer's Disease. <em>VTBIO Co. LTD</em>. https://clinicaltrials.gov/study/NCT03865017
Vancouver
Anonymous. A Safety and Tolerability Study of GB301 Given as a Single Intravenous Dose in Subjects With Mild to Moderate Alzheimer's Disease. VTBIO Co. LTD. 2019.
BibTeX
@misc{anon2019ASafet, title = {A Safety and Tolerability Study of GB301 Given as a Single Intravenous Dose in Subjects With Mild to Moderate Alzheimer's Disease}, author = {Anonymous}, journal = {VTBIO Co. LTD}, year = {2019}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings